Prolijune Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 19.00 Cr
as on 10-07-2024
- Paid Up Capital ₹ 4.91 M
as on 10-07-2024
- Company Age 18 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 5.88%
(FY 2017)
- Profit 5.62%
(FY 2017)
- Ebitda 7.35%
(FY 2017)
- Net Worth -12.82%
(FY 2017)
- Total Assets -1.80%
(FY 2017)
About Prolijune Lifesciences
The Corporate was formerly known as Prolijune. Exports. Private Limited.. The Company is engaged in the Financial Services Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 19.00 Cr and a paid-up capital of Rs 4.91 M, as per Ministry of Corporate Affairs (MCA) records.
Sheetal Arora, Eklavya Juneja, Prem Arora, and One other member serve as directors at the Company.
- CIN/LLPIN
U70100DL2006PTC153155
- Company No.
153155
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
06 Sep 2006
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
South Delhi, Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Prolijune Lifesciences?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Eklavya Juneja  | Director | 26-Dec-2017 | Current |
| Sheetal Arora | Director | 21-Jul-2011 | Current |
| Prem Arora | Director | 21-Jul-2011 | Current |
| Arjun Juneja | Director | 28-Jul-2011 | Current |
Financial Performance and Corporate Structure Insights of Prolijune Lifesciences.
Prolijune Lifesciences Private Limited, for the financial year ended 2017, experienced modest growth in revenue, with a 5.88% increase. The company also saw a slight improvement in profitability, with a 5.62% increase in profit. The company's net worth observed a substantial decline by a decrease of 12.82%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Prolijune Lifesciences?
In 2017, Prolijune Lifesciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Pathkind Diagnostics Private LimitedActive 8 years 2 monthsSheetal Arora, Eklavya Juneja and 1 more are mutual person
- Appian Buildheights LlpActive 7 years 6 months
Sheetal Arora, Prem Arora and 1 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Prolijune Lifesciences?
Unlock and access historical data on people associated with Prolijune Lifesciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Prolijune Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Prolijune Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
